- Bucladesine sodium
-
- $31.00 / 25mg
-
2024-11-05
- CAS:16980-89-5
- Min. Order:
- Purity: 99.58%
- Supply Ability: 10g
- Bucladesine sodium
-
- $31.00 / 25mg
-
2024-11-05
- CAS:16980-89-5
- Min. Order:
- Purity: 99.58%
- Supply Ability: 10g
|
| | Bucladesine sodium Basic information |
| Product Name: | Bucladesine sodium | | Synonyms: | dibutylcyclicampsodium;dibutylcyclicampsodiumsalt;dt5621sodiumsalt;e,butyrate(ester),monosodiumsalt;monosodiumdibutyrylcyclicamp;n-(9-beta-d-ribofuranosyl-9h-purin-6-yl)-butyramidcyclichydrogenphosphat;n6,02’-dibutyryladenosine3’,5’-cyclicmonophosphatesodiumsalt;n6,2’-o-dibutyryladenosine-3’,5’-cyclicmonophosphate(dbcamp),sodiumsalt | | CAS: | 16980-89-5 | | MF: | C18H25N5NaO8P | | MW: | 493.39 | | EINECS: | 241-059-4 | | Product Categories: | Cyclic Nucleotide related;API;16980-89-5 | | Mol File: | 16980-89-5.mol |  |
| | Bucladesine sodium Chemical Properties |
| Melting point | >173°C (dec.) | | storage temp. | -20°C | | solubility | H2O: 50 mg/mL | | form | powder | | color | white | | Merck | 14,1463 | | Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20° for up to 1 month. | | InChIKey | DBXVIQJWMFGXGO-AOTDUVMNNA-N | | SMILES | O([C@@H]1[C@]2([H])OP(O)(=O)OC[C@@]2([H])O[C@H]1N1C=NC2C(=NC=NC1=2)NC(=O)CCC)C(=O)CCC.[NaH] |&1:1,2,10,13,r| |
| Safety Statements | 24/25 | | WGK Germany | 2 | | RTECS | ES5055500 | | F | 10-21 | | HS Code | 29349990 |
| | Bucladesine sodium Usage And Synthesis |
| Description | Bucladesine sodium is a derivative of cyclic-AMP with cardiac stimulant and
peripheral vasodilatory properties. It is reported to be useful in cardiac
insufficiency, especially after heart surgery. | | Originator | Daiichi Seiyaku; Seishin Seiyaku (Japan) | | Uses | Bucladesine sodium is an analog of cyclic AMP that stimulates cAMP-dependent protein kinase. It has vasodilator properties and is used as a cardiac stimulant. | | Definition | ChEBI: Bucladesine sodium is a 3',5'-cyclic purine nucleotide. | | Application | N6,2′-O-Dibutyryladenosine 3′,5′-cyclic monophosphate sodium salt has been used:
as a medium supplement for neural crest stem cells (NCSCs) differentiation
as a component of thawing medium for cryopreserved human iPSC (induced pluripotent stem cell)-derived neurons
in serum-free Dulbecco′s modified eagle′s medium (DMEM) to induce astrocyte differentiation | | Brand name | ACTOCIN | | General Description | A cell-permeable cAMP analog that preferentially activates cAMP-dependent protein kinase (PKA). Causes an increase in the steady state level of parathyroid hormone-related peptide mRNA. Also acts as a Hh pathway antagonist. Shown to induce apoptosis in vascular smooth muscle cells. | | Biochem/physiol Actions | Cell-permeable cAMP analog that activates cAMP dependent protein kinase (PKA). | | storage | Store at -20°C | | References | 1) Bartsch?et al.?(2003),?Bioactivatable, membrane-permeant analogs of cyclic nucleotides as biological tools for growth control of C6 glioma cells; Biol. Chem.,?384?1321
2) Carranza?et al.?(1998),?Protein kinase A induces recruitment of active Na+,K+-ATPase units to the plasma membrane of rat proximal convoluted tubule cells; J. Physiol.,?15?511
3) Hei?et al.?(1991),?Lack of correlation between activation of cyclic AMP-dependent protein kinase and inhibition of contraction of rat vas deferens by cyclic AMP analogs; Mol. Pharmacol.,?39?233
4) Imamura?et al.?(1998),?Differential expression of dystrophin isoforms and utrophin during dibutyryl-cAMP-induced morphological differentiation of rat brain astrocytes; Proc. Natl. Acad. Sci. USA,?95?6139
5) Xia?et al.?(2016),?Transcriptional comparison of human induced and primary midbrain dopaminergic neurons; Sci. Rep.,?6?20270 |
| | Bucladesine sodium Preparation Products And Raw materials |
|